This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
We are sorry, but there is no personal subscription option available for your country.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Relling, M. V., Klein, T. E., Gammal, R. S., Whirl-Carrillo, M., Hoffman, J. M. & Caudle, K. E. The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clin. Pharmacol. Ther. 107, 171–175 (2020).
Berm, E. J. et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One 11, e0146262 (2016).
Kogan, J. N., Empey, P., Kanter, J., Keyser, D. J. & Shrank, W. H. Delivering on the value proposition of precision medicine: the view from healthcare payers. Am. J. Manag. Care 24, 177–179 (2018).
Hefti, E. & Blanco, J. G. Documenting pharmacogenomic testing with CPT codes. J. AHIMA 87, 56–59 (2016).
Palmetto, G. B. A. Local Coverage Determination (LCD): MolDX: Pharmacogenomics Testing (L38294). https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=38294&ver=16 (2020).
Caudle, K. E., Gammal, R. S., Whirl-Carrillo, M., Hoffman, J. M., Relling, M. V. & Klein, T. E. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am. J. Health Syst. Pharm. 73, 1977–1985 (2016).
Anderson, H. D., Crooks, K. R., Kao, D. P. & Aquilante, C. L. The landscape of pharmacogenetic testing in a US managed care population. Genet. Med. 22, 1247–1253 (2020).
Centers for Medicare & Medicaid Services. Who are the MACs. https://www.cms.gov/Medicare/Medicare-Contracting/Medicare-Administrative-Contractors/Who-are-the-MACs (2020).
US Food and Drug Administration. The FDA warns against the use of many genetic tests with unapproved claims to predict patient response to specific medications: FDA safety communication. https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-many-genetic-tests-unapproved-claims-predict-patient-response-specific (2018).
US Food and Drug Administration. Table of pharmacogenetic associations. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations (2018).
US Department of Health and Human Services. Rescission of guidances and other informal issuances concerning premarket review of laboratory developed tests. https://www.hhs.gov/coronavirus/testing/recission-guidances-informal-issuances-premarket-review-lab-tests/index.html (2020).
P.E.E. is a Co-Investigator on Implementing Genomics in Practice (IGNITE) project grant (U01 HG010245) and has provided consultative services for Cipherome. V.M.P. reports the following: the Indiana University School of Medicine Pharmacogenomics Laboratory is a fee-for-service clinical laboratory that offers clinical pharmacogenetic testing. V.M.P. is supported by the IGNITE project grants (U01 HG007762 and HG010245) and is on the clinical advisory board of Avalon Healthcare Solutions. J.M.H. is a Co-Investigator for CPIC (NIH/NHGRI U24HG010135). K.E.C. is the Co-Principal Investigator for CPIC (NIH/NHGRI U24HG010135). T.E.K. is the Co-Principal Investigator for the PharmGKB (NIH/NHGRI/NICHD U24 HG010615), CPIC (NIH/NHGRI U24HG010135) and PharmCAT (NIH/NHGRI U24 HG010862). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Empey, P.E., Pratt, V.M., Hoffman, J.M. et al. Expanding evidence leads to new pharmacogenomics payer coverage. Genet Med 23, 830–832 (2021). https://doi.org/10.1038/s41436-021-01117-w